Dr Susana Banerjee is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust and a Team Leader in Gynaecological Cancers (Systemic Therapy and Clinical Trials). Dr Banerjee specialises in ovarian cancer and advanced endometrial and cervical cancers.
Dr Banerjee graduated with a 1st class degree from St John's College, University of Cambridge and completed her medical training at Royal Free Medical School, where she was a University of London Gold Medal Finalist.
Dr Banerjee was awarded an Avon Breast Cancer Crusade Clinical Fellowship for laboratory research and gained a PhD in 2009 from The Institute of Cancer Research, London. In 2007, she was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research.
Other prizes include the Association of Cancer Physicians McElwain Prize, Sir Antony Driver Prize (ICR) and Pfizer British Oncology Association Young Investigator Award (highly commended). She completed specialist medical oncology training at The Royal Marsden and was appointed a Consultant in 2011. In June 2015, she re-joined the ICR and gained the title of Reader in Women’s Cancers at the ICR in 2019.
Dr Banerjee has been part of national and international specialist groups, including the National Cancer Research Institute Gynaecological Cancers Clinical Studies Group, European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, the European Society of Medical Oncology (ESMO) Gynaecological Cancers Faculty Faculty and ESMO Young Oncologists' Committee.
She continues to be part of the ESMO Women for Oncology Committee and is Chair of the ESMO Resilience Task Force. Dr Banerjee, elected ESMO Director of Membership (2020-2022), serves on the ESMO Executive Board. She is a member of the Medical Advisory Board for the Ovacome UK charity.
She is actively involved in clinical trials and translational research. Her research interests include individualisation of patient treatment and targeted therapies in gynaecological cancers including rare malignancies. Dr Banerjee has active collaborations with other ICR teams – Professor Chris Lord (Gene Function Team), Dr Rachael Natrajan (Functional Genomics), Professor Jessica Downs (Epigenetics and Genome Stability) and Professor Udai Banerji (Clinical Pharmacology and Trials).
She supervises MD(Res) and PhD students. Dr Banerjee is UK and Global Chief Investigator for a number of national and international clinical trials.